Perrigo (PRGO)
Health Care · Consumer Health Products · NYSE
Perrigo is a global provider of consumer self-care and over-the-counter health products designed to help individuals manage their personal health and wellness.
What Perrigo does
Perrigo is a provider of self-care and over-the-counter (OTC) health and wellness solutions. The company focuses on developing, manufacturing, and distributing consumer self-care products across a range of health categories globally. Its business model involves both internal brand development and strategic portfolio management through divestitures of non-core assets.
Themes: Self-care / consumer health, OTC medications, Consumer wellness
Fundamentals
- Price$14.50 as of 2026-10-08 close
- Market cap$2.0B as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return-33.0% 2025-10-08 close $21.65 → 2026-10-08 close $14.50
- P/En/a negative earnings
- Net margin-33.5% FY2025, SEC XBRL
- Gross margin+35.1% FY2025, SEC XBRL
- ROE-48.6% FY2025, SEC XBRL
- Debt / equity1.31 as of 2026-09-02
- Revenue growth (YoY)-4.2% as of 2026-09-02
- Revenue CAGR (3y)-1.5% SEC XBRL
- Beta0.85 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +8.6%; at least 14 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How PRGO compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldtop 10% 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PRGO is not currently in any published Top 10 list. Its scores are below.
Top 10 score
36.9 #1254 of 1,379 scored · #138 of 151 in Health Care
Valuation 98th (price to book 0.8) and capital return 59th (consecutive years of dividend increases 14 years, net share count bought back over the year -0.8); weakest is profitability (4th, return on equity -48.6%, operating margin -26.4%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, PRGO's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 110%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout110% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Perrigo looks technically
Perrigo (PRGO) is trading 17.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day high about 10 trading days ago. It is 36.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.69 | $13.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.35 | $12.35 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 15.69. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal | 20 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($13.61 to $15.69) — its "stochastic" reading is 43 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 42.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $22.65 | $22.65 |
|---|---|---|
| From the 52-week high | it is 36.0% below its 52-week high (its highest price of the past year) | -36.0% |
| Above the 52-week low | it is 57.2% above its 52-week low (its lowest price of the past year) | +57.2% |
| Below the 52-week high | it is 36.0% below its highest point of the past year | 36.0% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $215.73 (set on 2015-04-08) | $215.73 |
| Given back of the 52-week move | over the past year its closes ranged ($9.25 to $22.51), and it has recovered roughly a third of its fall from last year’s high — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.44 to $17.87. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.6% |
| From the all-time high | it is 93.3% below its all-time high | -93.3% |
| Nearest price level | it is trading 3.1% below a resistance level at $14.96 — a price it turned at three times since 2026-02-04, most recently on 2026-09-04. Since 2024-10-08 it has 7 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.1% |
| All-time low | its lowest closing price on record is $9.22 (set on 2026-03-20) | $9.22 |
| Above the all-time low | it is 57.2% above its all-time low | +57.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 32nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6354 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6354 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.10 and $15.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.10 – $14.22 – $15.35 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (17.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.05× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Open gap | it gapped 3.2% above the previous close 13 sessions ago and has not traded back through the level it left behind at 13.56 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.2% |
| Gap filled | a 2.1% gap down opened on 2026-08-12 has been "filled" 39 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 39 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.6 percentage points (the stock lost 0.5% while the market gained 1.0%) | -1.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 34.0 percentage points (the stock gained 37.8% while the market gained 3.8%) | +34.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 19.5 percentage points (the stock gained 36.9% while the market gained 17.5%) | +19.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.0 percentage points (the stock lost 33.0% while the market gained 15.0%) | -48.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +8.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $12.16 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +19.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $13.99 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | +3.7% |
Price levels it has turned at before
PRGO last closed at $14.50 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.96 | Resistance | 3.1% above the last close | turned there three times · 2026-02-04 to 2026-09-04 |
| $13.62 | Support | 6.1% below the last close | turned there twice · 2026-01-29 to 2026-08-05 |
| $12.66 | Support | 12.7% below the last close | turned there twice · 2025-12-16 to 2026-05-06 |
| $12.16 | Support | 16.2% below the last close | turned there three times · 2025-11-21 to 2026-08-12 |
| $20.64 | Resistance | 42.3% above the last close | turned there twice · 2025-09-22 to 2025-10-10 |
| $23.87 | Resistance | 64.6% above the last close | turned there three times · 2025-02-19 to 2025-04-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $15.69.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · beating the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$16.50 range $14.00 – $20.00; median $16.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRGO
- Consensus EPS estimate$0.5319 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 (0.0%) from $0.5319, on 2026-08-30, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Potential impairment charges related to the carrying amount of specific assets.","Significant competition from industry participants with larger market shares or marketing resources.","Risks associated with the integration of acquisitions and the realization of expected benefits from strategic divestitures and restructuring programs."]
What changed in the latest 10-Q
AI-assisted comparison of PRGO's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing) vs. December 31, 2024 (older filing)
- Reference to Item 1A of 2025 Form 10-K (newer) vs. 2024 Form 10-K (older)
- Quotation marks around 'Perrigo' in corporate description in newer filing
- New reporting segment structure: Self Care, Specialty Care, Infant Formula, and All Other (replacing CSCA and CSCI segments)
- New products table detailing product categories across reporting segments
- Products organized by Self Care (Upper Respiratory, Digestive Health, Healthy Lifestyle, Pain and Sleep-Aids), Specialty Care (Skin Health, Women's Health), Infant Formula, and All Other (Oral Care, Other)
- Reference to Opill ® and Mederma ® as brands in North America section
- Note that Dermacosmetics business is now included within Other category (previously in Skin Care)
- Phrase 'healthy lifestyle and women's health' replaces 'nutrition and women's health' in North America description
- Removed:
- Reference to Supply Chain Reinvention Program and Project Energize initiatives (previously detailed)
- Detailed explanation of complementary businesses with mention of 'store brands and infant formula' and 'High-Grow' brands
- Statement about 'leveraging global supply chain scale with 100-plus molecules, at 100% consumer price point coverage'
- Detailed 'Three-S' plan description specifying stabilizing 'Consumer Self-Care Americas store brand and infant formula businesses,' streamlining 'global portfolio, enterprise operating model and Consumer Self-Care International business,' and strengthening 'High-Grow' brands
- Operating segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI)
- Recent Developments section (including KKR Dermacosmetics Business sale and infant formula strategic review announcements)
- Reference to Note 5 (changed to Note 4 in newer filing)
- Reworded:
- Strategic goal description changed from listing four numbered items to simplified language about 'sustainable and value accretive growth' with numbered items reordered
- 'Three-S' plan simplified from specific business references to general 'Stabilizing,' 'Streamlining,' and 'Strengthening' language without detailed context
- North America product categories: 'nutrition' removed and 'healthy lifestyle' added as category descriptor
- Complementary business explanation condensed significantly, removing detailed cash generation and investment mechanics
- Supply chain scale description changed from 'global supply chain scale and reach with 100-plus molecules, at 100% consumer price point coverage' to 'global supply chain scale with more molecules at more price points to more consumers'
- Notes:
- Older filing text appears truncated at 'Restructuring Supply Chain Reinve' - comparison limited to complete text available
- Segment structure fundamentally changed from geographic (CSCA/CSCI) to product-category based (Self Care, Specialty Care, Infant Formula, All Other), suggesting material reorganization
- Recent Developments section entirely removed from newer filing, though this may reflect timing of the 10-Q periods rather than deletion of information
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for PRGO — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
PRGO had 22,639,002 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
PRGO had 16.3% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.34 days to cover at the same settlement.
- Reported short interest (shares) 22,639,002
- Short interest (% of shares outstanding) 16.3%
- Prior settlement (shares) 22,559,388
- Reported change 0.35%
- Days to cover (reported) 9.34
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Johnson & Johnson (JNJ)
- Haleon
- Procter & Gamble (PG)
- Sanofi (SNY)
- GSK (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRGO vs…
Frequently asked questions
What does Perrigo (PRGO) do?
Perrigo is a provider of self-care and over-the-counter (OTC) health and wellness solutions. The company focuses on developing, manufacturing, and distributing consumer self-care products across a range of health categories globally. Its business model involves both internal brand development and strategic portfolio management through divestitures of non-core assets.
What sector is Perrigo (PRGO) in?
Perrigo (PRGO) is classified in the Health Care sector. Its industry is Consumer Health Products. It trades on NYSE.
Does PRGO pay a dividend?
Yes — Perrigo (PRGO) pays a dividend, with an indicated yield of about 8.55% and at least 14 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-02). Informational only — not financial advice.
Who are Perrigo's (PRGO) competitors?
Notable peers of Perrigo (PRGO) include Johnson & Johnson, Haleon, Procter & Gamble, Sanofi and GSK. This peer set is informational only — not financial advice.
Is Perrigo (PRGO) overbought or oversold right now?
Perrigo (PRGO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRGO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.